Cargando…
Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report
Patients with multiple sclerosis (MS) repeatedly receive therapies that cause B-lymphocyte depletion. This may lead to abnormal immune responses following coronavirus disease 2019 (COVID-19) vaccination, as has been suggested previously. We therefore evaluated post-vaccination immune responses in a...
Autores principales: | Mado, Hubert, Kubicka-Bączyk, Katarzyna, Adamczyk-Sowa, Monika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451259/ https://www.ncbi.nlm.nih.gov/pubmed/34528472 http://dx.doi.org/10.1177/03000605211044378 |
Ejemplares similares
-
COVID-19-Vaccine-Pfizer-BioNTech/ocrelizumab: Vaccine failure: case report
Publicado: (2021) -
Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations
por: Mado, Hubert, et al.
Publicado: (2021) -
Myocarditis with Pfizer-BioNTech's COVID-19 vaccine in Israel
Publicado: (2021) -
Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
Publicado: (2021) -
Pfizer-BioNTech COVID-19 vaccine safe in children
Publicado: (2022)